Brexpiprazole

Overview

Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and as an adjunct in major depressive disorder. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors.

Patent & exclusivity (US)

Per the FDA Orange Book (12 approved US products), the latest listed US patent on Brexpiprazole expires 11 Apr 2033 and exclusivity 8 May 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

3,5,5-trimethyl-1,3-oxazolidine-2,4-dione

Canonical SMILES

CC1(C(=O)N(C(=O)O1)C)C

InChIKey

IRYJRGCIQBGHIV-UHFFFAOYSA-N

Therapeutic areas